Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-01-13 Major Shareholding Noti…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
Sequana Medical - January 2025 - Transparency Notification Belfius PR (ENG).pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparency Notification from Shareholders" and explicitly states that the company received a notification regarding the number of voting rights held by certain entities, detailing the change in percentage of total outstanding shares. The content focuses on the acquisition or disposal of voting securities, crossing ownership thresholds (3%, 5%, 10%), and references the Belgian Act on the disclosure of major participations. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. Although it is presented as a press release, the core subject matter is the change in major shareholding.
2025-01-13 English
Sequana Medical - January 2025 - Transparency Notification Belfius PR (NL).pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparantiekennisgeving van Aandeelhouders" (Shareholder Transparency Notification) and details the acquisition or disposal of voting rights by specific entities (Société Fédérale de Participations et d'Investissement SA / Belfius). It explicitly mentions compliance with Article 14 of the Belgian law of May 2, 2007, regarding the disclosure of major shareholdings, and references thresholds (3%, 5%, 10%, etc.). This type of mandatory disclosure regarding changes in significant ownership stakes directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release ("PERSBERICHT GEREGLEMENTEERDE INFORMATIE"), the core content is the notification of a change in shareholding percentage that crosses a regulatory threshold.
2025-01-13 Dutch
Sequana Medical - Minutes EGM December 2024.pdf
AGM Information Classification · 99% confidence The document text is a formal notarial record detailing the proceedings of a 'BUITENGEWONE ALGEMENE VERGADERING' (Extraordinary General Meeting) of Sequana Medical. It covers the verification of attendees, quorum requirements, voting modalities, and the date of the meeting (December 20, 2024). This content directly relates to the formal meeting process and the results/procedures thereof. While it is a record of the meeting, the primary focus is on the meeting itself, which aligns best with the 'AGM Information' category, even though it is an EGM (Extraordinary General Meeting) record, as there is no specific code for EGM records, and AGM-R covers general meeting materials. It is not a DEF 14A (Remuneration), DVA (Declaration of Voting Results - although voting is discussed, this is the procedural record), or a CT (Call Transcript). Given the context of a formal meeting record, AGM-R is the most appropriate fit.
2024-12-20 Dutch
Sequana Medical - December EGM 2024 Results PR + CLA Update (ENG).pdf
Capital/Financing Update Classification · 99% confidence The document is explicitly titled as a "PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION" dated December 20, 2024. It announces two main events: 1) The results of an Extraordinary General Meeting (EGM) where shareholder resolutions were approved (related to subscription rights), and 2) An update on a Convertible Financing/Bridge Loan, including new investor commitments and the resulting aggregate principal amount. The announcement of voting results from a general meeting points strongly towards DVA (Declaration of Voting Results & Voting Rights Announcements). The announcement of financing/loan commitments points towards CAP (Capital/Financing Update). Since the document covers both a shareholder vote result and a significant financing update, and it is presented as a formal press release, it fits the criteria for both DVA and CAP. However, the primary focus seems to be the corporate actions resulting from the meeting and the financing update. Given the explicit mention of 'results of Extraordinary General Meeting of Shareholders' and the approval of resolutions, DVA is highly relevant. The financing update is also a key component. Since the document is a comprehensive press release detailing corporate actions rather than just a short notice, it is not an RPA. Because it details the outcome of a shareholder vote, DVA is a strong candidate. Because it details a financing commitment, CAP is also strong. In cases where both corporate governance action results (DVA) and financing updates (CAP) are present in a single press release, we must choose the most encompassing or primary theme. The document leads with the EGM results. Furthermore, the financing update is structured as an 'update on Convertible Financing' which is a capital activity. Since the document is a full press release detailing these events, and not just a short notice, we must select the most appropriate code. Given the dual nature, and the fact that financing updates (CAP) are often detailed in press releases, and EGM results are covered by DVA, I will prioritize the announcement of the financing/capital structure change (CAP) as it involves concrete financial commitments, while acknowledging the DVA element. However, looking closely at the definitions, DVA covers 'Official results from shareholder votes at any general meeting (AGM or EGM)'. This is explicitly stated. Let's re-evaluate. The document explicitly states the resolution was approved at the EGM. This is a direct match for DVA. The financing update is secondary information within the same release. Therefore, DVA is the most precise fit for the first major announcement.
2024-12-20 English
Sequana Medical - December EGM 2024 Results PR + CLA Update (NL).pdf
AGM Information Classification · 99% confidence The document is titled "PERSBERICHT GEREGLEMENTEERDE INFORMATIE" (Regulated Information Press Release) and announces two main events: 1) The approval of resolutions at an Extraordinary General Meeting of Shareholders (Buitengewone Algemene Vergadering van Aandeelhouders) concerning share rights, and 2) An update on convertible financing (Converteerbare Financiering) where existing investors committed additional funds. The content focuses on shareholder meeting outcomes and capital structure/financing activities. The key elements point towards an announcement related to capital changes and shareholder meetings. Since it specifically mentions the results of a shareholder vote (AGM/EGM related) and significant financing updates (capital/financing), the most fitting categories are AGM-R (for the meeting results) or CAP (for the financing update). Given that the primary focus is on the approval of resolutions from a General Meeting and the subsequent financing update, and the document is a press release announcing these events rather than the full minutes or the final financing agreement, it strongly aligns with announcements related to capital structure changes (CAP) and shareholder meetings (AGM-R). However, the financing update (EUR 0.55 million commitment to the Convertible Bridge Loan) is a significant component, falling directly under Capital/Financing Update (CAP). The shareholder meeting results are also announced. Since the document covers both the outcome of a shareholder meeting (AGM-R territory) and a capital/financing update (CAP territory), and the financing update is substantial, I will prioritize the financing aspect as it involves new commitments and loan structures, which is a core function of CAP. If the document were solely about the voting results, AGM-R would be better. If it were solely about the financing, CAP would be better. Since it covers both, and the financing update is detailed, CAP is a strong fit, but AGM-R is also highly relevant due to the explicit mention of the EGM results. Given the structure of the definitions, a document announcing the results of a general meeting falls under AGM-R, even if it contains other news. The document explicitly states the resolutions proposed to the EGM were approved. Therefore, AGM-R is the most precise fit for the meeting component, while CAP covers the financing component. I will select AGM-R as the primary classification because the document leads with the EGM results and the financing update is presented as a secondary announcement within the same press release structure often used for combined news releases following a meeting.
2024-12-20 Dutch
Convertible loan date -- Announcement Press Release ENG vF.pdf
Capital/Financing Update Classification · 98% confidence The document is a press release titled "SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN". It discusses an extension of a deadline related to a loan agreement and financing terms. This content directly relates to the company's capital structure, fundraising, and financing activities. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it is a specific announcement about financing terms, it is more specific than a general Regulatory Filing (RNS).
2024-12-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.